DDInter351 DDInter1819
An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022]
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Chloramphenicol {u} (Compound) binds {v} (Gene) CYP3A5
Chloramphenicol {u} (Compound) upregulates {v} (Gene) CCNH
Chloramphenicol {u} (Compound) is included by {v} (Pharmacologic Class) Amphenicols
Chloramphenicol {u} (Compound) downregulates {v} (Gene) USP22
Chloramphenicol {u} (Compound) causes {v} (Side Effect) Angioedema
Chloramphenicol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Chloramphenicol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elotuzumab
Chloramphenicol {u} may lead to a major life threatening interaction when taken with {v} Flibanserin
Chloramphenicol (Compound) binds CYP3A5 (Gene)
Chloramphenicol (Compound) upregulates CCNH (Gene)
Chloramphenicol (Compound) is included by Amphenicols (Pharmacologic Class)
Chloramphenicol (Compound) downregulates USP22 (Gene)
Chloramphenicol (Compound) causes Angioedema (Side Effect)
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Donepezil
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Chloramphenicol may lead to a major life threatening interaction when taken with Flibanserin